MedTrace Logo

Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19)

NCT04425759 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2400

Last updated 2020-06-16

No results posted yet for this study

Summary

Observational and prospective study with one year of follow-up of the cohort of workers of the CSdM, including workers of subcontracted companies working in the Hospital of Mataró (2,300 workers approximately) and with controls at baseline and at 3, 6, 9 and 12 months. All CSdM workers will be invited to participate by e-mail and by announcements in the corporate website. A space will be set up on the corporate intranet where workers will be informed about the study, will be able to give their informed consent and will be able to answer an electronic questionnaire regarding socio-demographic, clinical and labour personal characteristics. Once the questionnaire answered, participants will be authorized to schedule a blood extraction. Prevalence of antibodies against SARS-CoV-2 will be analyzed (IgA, IgM, IgG). PCR will be also performed for IgM and IgA positive subjects.

Conditions

  • Covid19
  • Corona Virus Infection
  • SARS-CoV 2
  • COVID

Interventions

DIAGNOSTIC_TEST

Blood sample

Blood sammples for the serological analysis will be collected at 0/90/180/270/360 days.

Sponsors & Collaborators

  • Hospital de Mataró

    lead OTHER

Principal Investigators

  • Pere Clavé, MD, PhD · Hospital de Mataró

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04425759 on ClinicalTrials.gov